Post-CAR-T cell therapy presenting as proteinaceous lymphadenopathy

Mishi Bhushan, Kirthi R. Kumar

Research output: Contribution to journalArticlepeer-review


Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma and is often treated with chemotherapy, autologous stem cell transplant, and chimeric antigen receptor (CAR-T) cell therapy. Despite the increasing use of CAR-T therapy in various hematolymphoid malignancies, very little is known about pathologic effects on various tissues. We report a case of diffuse large B-cell lymphoma treated with CAR-T, with suspected relapse on PET scan. Pathology from an excisional biopsy showed no evidence of persistent diffuse large B-cell lymphoma, but instead showed extensive deposition of PAS positive, acellular material, consistent with proteinaceous lymphadenopathy. There is little known pathologic effects on malignant tissue following CAR-T therapy and we present one such undocumented finding of post-CAR-T cell therapy-induced proteinaceous lymphadenopathy.

Original languageEnglish (US)
Article number200475
JournalHuman Pathology: Case Reports
StatePublished - Mar 2021


  • CAR-T
  • Lymphoma
  • Proteinaceous lymphadenopathy

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Dive into the research topics of 'Post-CAR-T cell therapy presenting as proteinaceous lymphadenopathy'. Together they form a unique fingerprint.

Cite this